CVS Health Corp (CVS)vsNasdaq Inc (NDAQ)
CVS
CVS Health Corp
$95.89
-1.30%
HEALTHCARE · Cap: $125.18B
NDAQ
Nasdaq Inc
$90.93
-0.67%
FINANCIAL SERVICES · Cap: $51.42B
Smart Verdict
WallStSmart Research — data-driven comparison
CVS Health Corp generates 7385% more annual revenue ($405.62B vs $5.42B). NDAQ leads profitability with a 35.3% profit margin vs 0.7%. CVS appears more attractively valued with a PEG of 0.26. NDAQ earns a higher WallStSmart Score of 69/100 (B-).
CVS
Buy65
out of 100
Grade: C+
NDAQ
Strong Buy69
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+77.8%
Fair Value
$346.22
Current Price
$95.89
$250.33 discount
Intrinsic value data unavailable for NDAQ.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Earnings expanding 63.1% YoY
Large-cap with strong market position
Reasonable price relative to book value
Generating 3.4B in free cash flow
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 48.4%
Large-cap with strong market position
Earnings expanding 33.8% YoY
Areas to Watch
ROE of 3.8% — below average capital efficiency
0.7% margin — thin
Operating margin of 4.1%
Elevated debt levels
Expensive relative to growth rate
Moderate valuation
Comparative Analysis Report
WallStSmart ResearchBull Case : CVS
The strongest argument for CVS centers on PEG Ratio, EPS Growth, Market Cap. PEG of 0.26 suggests the stock is reasonably priced for its growth.
Bull Case : NDAQ
The strongest argument for NDAQ centers on Profit Margin, Operating Margin, Market Cap. Profitability is solid with margins at 35.3% and operating margin at 48.4%. Revenue growth of 13.7% demonstrates continued momentum.
Bear Case : CVS
The primary concerns for CVS are Return on Equity, Profit Margin, Operating Margin. A P/E of 43.0x leaves little room for execution misses. Thin 0.7% margins leave little buffer for downturns.
Bear Case : NDAQ
The primary concerns for NDAQ are PEG Ratio, P/E Ratio.
Key Dynamics to Monitor
CVS profiles as a value stock while NDAQ is a mature play — different risk/reward profiles.
NDAQ carries more volatility with a beta of 0.99 — expect wider price swings.
NDAQ is growing revenue faster at 13.7% — sustainability is the question.
CVS generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
NDAQ scores higher overall (69/100 vs 65/100), backed by strong 35.3% margins and 13.7% revenue growth. CVS offers better value entry with a 77.8% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CVS Health Corp
HEALTHCARE · HEALTHCARE PLANS · USA
CVS Health (previously CVS Corporation and CVS Caremark Corporation) is an American healthcare company that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; Aetna, a health insurance provider, among many other brands. The company's headquarters is in Woonsocket, Rhode Island.
Visit Website →Nasdaq Inc
FINANCIAL SERVICES · FINANCIAL DATA & STOCK EXCHANGES · USA
Nasdaq, Inc. is an American multinational financial services corporation that owns and operates stock exchanges in the United States and Europe. It is headquartered in New York City.
Visit Website →Compare with Other HEALTHCARE PLANS Stocks
Want to dig deeper into these stocks?